- Launched First Time in India, patented in India and South Africa.
- Tobracef is excellent choice against MDR gram -ve pathogens.
- Tobracef shows synergistic effect (Acc. to martindale : page :-234) so as to overcome resistant strains of producing pathogens like Pseudomonas , E.coli, K.pneumoniae, Enterobacteriacae etc.
- Tobracef as a brand shows reduction in Oxidative stress and lipid peroxidation, so it’s safe to renel tissues as compared to Tobramycin and ceftazidime alone.
- Tobracef prevents the skin graft failure by inhibiting gram-ve pathogens like Psudomonas aeruginosa, Enterobacteriacae etc. Tobracef is availabe with super solvent which shows following advantages.
- Tobracef breaks gylcocalyx and enhance drug up take up to 85.3 %.
- Tobracef works at lower MIC value.
- Tobracef shows 89 % susceptibility in MDR gram negative pathogens.
- Clinical success rate of Tobracef is 88.4 %.
